Loading...
Market
What will be Pfizer's danuglipron market share among weight-loss medications by the end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports or Pfizer's financial reports
Story
Pfizer Advances Development of Once-Daily Weight-Loss Pill Danuglipron with 2024 Trials
Jul 11, 2024, 12:04 PM
Pfizer is advancing the development of a once-daily formulation of its experimental weight-loss pill, danuglipron, which targets the multibillion-dollar market for obesity medications. The company announced on Thursday it will conduct dose optimization studies in the second half of 2024 after obtaining promising pharmacokinetic results for the modified release formulation. This decision follows the scrapping of a twice-daily version of the drug late last year. Danuglipron is a GLP-1 receptor agonist, and Pfizer aims to determine the optimal dosage in upcoming clinical trials later this year after getting promising data from an early-stage trial.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 34%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%